Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 Therapy for Metastatic Cancer
NCT07197671Phase 1Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of 90Y-NM600 in metastatic cancer (7 arms), sponsored by University of Wisconsin–Madison. Primary endpoints: Toxicities greater than or equal to Grade 3 at least possibly related to 86Y-NM600 and Toxicities greater than or equal to Grade 3 at least possibly related to 90Y-NM600. Started Nov 2026; status: recruiting.
02
Drugs
90Y-NM600
03
Conditions
metastatic cancer
Beyond the preview
Go deeper on NCT07197671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07197671.